new york times glp 1 What Older Adults Should Know About GLP-1 Drugs as Medicare Coverage Expands Opinion | If Kids Need
Description
the small-molecule world will look to do the same, but likely as fixed-dose combinations of two or three orals rather than as single multi-functional peptides until true dual and triple small-molecule agonists can be found
Novo Nordisk signs deal for monthly GLP-1 agonist Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases
Description text goes hereSemaglutide
A 2025 report found 63% of patients remained on GLP-1s after one year , up from previous years ( [66] ), and easier PA processes may be one factor
Clifford, S
